Repositioning Candidate Details

Candidate ID: R1412
Source ID: DB11834
Source Type: approved; investigational
Compound Type: biotech
Compound Name: Guselkumab
Synonyms: Guselkumab
Molecular Formula: --
SMILES: --
DrugBank Description: Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
CAS Number: 1350289-85-8
Molecular Weight:
DrugBank Indication: Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DrugBank Pharmacology: Guselkumab is shown to reduce serum levels of IL-17A, IL-17F and IL-22 .
DrugBank MoA: Guselkumab targets the p19 alpha subunit of IL-23. While IL-23 promotes the normal inflammatory and immune responses, the p19 and p40 subunits of IL-23 are found to be over-expressed in the condition of psoriasis and other autoimmune inflammatory skin diseases . Guselkumab selectively binds to the p19 subunit of IL-23 in dendritic cells and keratinocytes and blocks its interaction with IL-23 receptor, which further prevents the release of other pro-inflammatory cytokines and chemokines via stimulation of immune cells such as Th17 cells . Thus, guselkumab blocks the abnormally-heightened signalling of inflammatory cascades that promote epidermal abnormalities including keratinocyte hyperproliferation and psoriatic plaque formation .
Targets: Interleukin-23 subunit alpha blocker
Inclusion Criteria: Therapeutic strategy associated